Cell death in head and neck cancer pathogenesis and treatment

RAUDENSKÁ, Martina, Jan BALVAN and Michal MASAŘÍK. Cell death in head and neck cancer pathogenesis and treatment. CELL DEATH & DISEASE. LONDON: NATURE PUBLISHING GROUP, 2021, vol. 12, No 2, p. 1-17. ISSN 2041-4889. Available from: https://dx.doi.org/10.1038/s41419-021-03474-5.

Basic information

Original name

Cell death in head and neck cancer pathogenesis and treatment

Authors

RAUDENSKÁ, Martina (203 Czech Republic, belonging to the institution), Jan BALVAN (203 Czech Republic, belonging to the institution) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution)

Edition

CELL DEATH & DISEASE, LONDON, NATURE PUBLISHING GROUP, 2021, 2041-4889

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 9.685

RIV identification code

RIV/00216224:14110/21:00119012

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41419-021-03474-5

UT WoS

000621062800002

Keywords in English

Cell death; head and neck cancer; pathogenesis; treatment

Tags

14110515, 14110518, rivok

Tags

International impact, Reviewed

---

Abstract

V originále

Many cancer therapies aim to trigger apoptosis in cancer cells. Nevertheless, the presence of oncogenic alterations in these cells and distorted composition of tumour microenvironment largely limit the clinical efficacy of this type of therapy. Luckily, scientific consensus describes about 10 different cell death subroutines with different regulatory pathways and cancer cells are probably not able to avoid all of cell death types at once. Therefore, a focused and individualised therapy is needed to address the specific advantages and disadvantages of individual tumours. Although much is known about apoptosis, therapeutic opportunities of other cell death pathways are often neglected. Molecular heterogeneity of head and neck squamous cell carcinomas (HNSCC) causing unpredictability of the clinical response represents a grave challenge for oncologists and seems to be a critical component of treatment response. The large proportion of this clinical heterogeneity probably lies in alterations of cell death pathways. How exactly cells die is very important because the predominant type of cell death can have multiple impacts on the therapeutic response as cell death itself acts as a second messenger. In this review, we discuss the different types of programmed cell death (PCD), their connection with HNSCC pathogenesis and possible therapeutic windows that result from specific sensitivity to some form of PCD in some clinically relevant subgroups of HNSCC.

---

Links

GA18-03978S, research and development project	Name: Efekt buněčné tuhosti a mikroprostředí jako prediktor odpovědi na léčbu karcinomů hlavy a krku Investor: Czech Science Foundation
MUNI/A/1246/2020, interní kód MU	Name: Kardiovaskulární systém: od iontového kanálu k celotělovému modelu (Acronym: KAVASYKAMO) Investor: Masaryk University
MUNI/A/1698/2020, interní kód MU	Name: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Acronym: ComplexPF) Investor: Masaryk University
NU20J-08-00018, research and development project	Name: Exosomální RNA produkovaná fibroblasty asociovanými s nádorem jako relevantní marker v prognóze nádorů hlavy a krku Investor: Ministry of Health of the CR, Subprogram 2 - junior